Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…
en_news
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…
Results of the DUTHY exploratory phase II study evaluating dual immune checkpoint blockade with durvalumab and tremelimumab show promising activity…
Presented at the 2022 annual Congress of the European Society for Medical Oncology (ESMO), results from three studies co-authored by…
Dr Enriqueta Felip, head of the Thoracic Tumours and Head and Neck Cancer Group at VHIO and section head in…
After an initial response to approved tyrosine kinase inhibitors, principally imatinib, most patients with GIST will develop acquired cancer drug…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
The five-year follow up data from patients in the KEYNOTE-048 trial have been reported, with the participation of Dr. Irene…
Results of long-term survival analysis of the phase III EMPOWER-Cervical 1 multicenter clinical trial show that immune checkpoint inhibitor cemiplimab…
The first pre-specified interim analysis of overall survival data from the phase III IMpower010 trial shows a trend in favor…
